Fonterelli SPAC 2 Aktie 118813979 / DE000A3MQR65
Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
---|---|---|---|---|---|---|
Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
Orderbuch | Analysen | |||||
Historisch |
01.10.2025 09:33:14
|
EQS-News: Viromed Medical AG drives forward market launch of new products in the first half of 2025 and expands strategic partnerships
EQS-News: Viromed Medical AG
/ Key word(s): Half Year Report/Half Year Results
PRESS RELEASE Viromed Medical AG drives forward market launch of new products in the first half of 2025 and expands strategic partnerships Rellingen, October 01, 2025 – Viromed Medical Group ("Viromed"; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology, has published its 2025 half-year report, which includes consolidated interim financial statements for the first time. The company can look back on a successful first half of 2025, which was marked by a strategic acquisition, new collaborations, and promising study results. Operational activities focused on the development of further products based on innovative cold plasma technology, preparations for approvals, and the conduct of preclinical and clinical studies. With the integration of pharmedix GmbH, Viromed expanded its portfolio to include healthcare products in the fields of medicine, nutrition, and cosmetics. The collaboration with relyon plasma GmbH secured the series production of the innovative cold plasma products ViroCAP® and PulmoPlas®. Viromed also made significant progress in clinical development: initial results in the treatment of ventilator-associated pneumonia (VAP) in intensive care patients confirmed the high potential of PulmoPlas®. This was complemented by exclusive distribution partnerships in Asia, in the veterinary sector, and in the European cosmetics market, which are opening up new growth markets. Recent preclinical study data from the Hannover Medical School (MHH) underscore the great medical potential of cold plasma therapy, which could prevent thousands of deaths each year. With the first-time consolidation of Viromed Medical AG, Viromed Medical GmbH, and pharmedix GmbH, the economic situation is now presented at group level. Consolidated revenues of EUR 2.4 million were achieved in the first half of 2025. Overall, there was a net loss for the period of EUR 0.8 million, mainly due to expenses for the preparation of the market launch of ViroCAP® and PulmoPlas®. The company's equity amounted to EUR 6.6 million as of June 30, 2025, corresponding to an equity ratio of 39.9%. Viromed plans significant growth for 2025 and confirms its forecast for the full year. The Viromed Medical Group's revenue is expected to rise from EUR 1.37 million in 2024 to between EUR 8 million and EUR 10 million. The company also expects a slightly positive result, primarily driven by the operating business of the acquired pharmedix GmbH. The 2025 half-year financial statements are available on the Viromed Medical AG website.
About Viromed Medical AG Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region and beyond. Viromed is pursuing the goal of further advancing the use of cold plasma technology in medicine in the coming years and realizing the corresponding growth potential.
E-Mail: kontakt@viromed-medical.de Press contact E-mail: viromed@kirchhoff.de
01.10.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
Language: | English |
Company: | Viromed Medical AG |
Hauptstrasse 105 | |
25462 Rellingen | |
Germany | |
E-mail: | kontakt@viromed-medical.de |
Internet: | https://www.viromed-medical-ag.de/ |
ISIN: | DE000A3MQR65 |
WKN: | A3MQR6 |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Hamburg, Tradegate Exchange |
EQS News ID: | 2206704 |
End of News | EQS News Service |
|
2206704 01.10.2025 CET/CEST
Nachrichten zu Fonterelli SPAC 2 AG Inhaber-Akt
Analysen zu Fonterelli SPAC 2 AG Inhaber-Akt
Let’s talk about Börsenjahr 2025 | Börsentag Zürich 2025
Ein besonderes Highlight des Börsentag Zürich 2025 war die grosse Diskussionsrunde mit:
👉 Thomas B. Kovacs (Sparkojote)
👉 Robert Halver (Baader Bank)
👉 Tim Schäfer (Finanzblogger, New York)
👉 Lars Erichsen (Börsencoach & YouTuber)
👉 David Kunz (COO, BX Swiss)
Gemeinsam analysieren sie die Entwicklungen an den Finanzmärkten 2025, teilen Einschätzungen zu aktuellen Trends und geben spannende Einblicke für Anleger.
📌 Themen im Fokus:
🔹Welche Krisen & geopolitischen Risiken beschäftigen die Märkte wirklich?
🔹Wie wirken sich Zölle speziell auf die Schweiz und ihre Exportwirtschaft aus?
🔹Zinspolitik: Unterschiede zwischen USA, Europa und Schweiz.
🔹Aktien vs. Immobilien: Welche Assetklasse lohnt sich 2025 mehr?
🔹Künstliche Intelligenz – Hype oder langfristiger Wachstumstreiber?
🔹Gold vs. Bitcoin: Welches Asset ist der bessere Schutz im Depot?
🔹Inflation, Liquidität und Notenbanken: Warum Sachwerte profitieren.
🔹Blick in die Glaskugel: Wo stehen Aktien & Krypto Ende 2025?
👉🏽 Jetzt auch auf BXplus anmelden und von exklusiven Inhalten rund um Investment & Trading profitieren!
Inside Trading & Investment
Mini-Futures auf SMI
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
US-Medikamentendeal treibt an: Dow stabil -- SMI fester -- DAX wechselt ins Positive -- Nikkei schliesst niedriger - China-Börsen geschlossenDer heimische Markt notiert zur Wochenmitte im Plus, der deutsche Leitindex schüttelt anfängliche Verluste ab. Dagegen tritt der Dow auf der Stelle. Der japanische Leitindex gab zur Wochenmitte nach, die China-Börsen blieben daneben feiertagsbedingt geschlossen.
finanzen.net News
Datum | Titel |
---|---|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |